Lupin Ltd has moved to resolve a key legal overhang in the US, with its wholly owned subsidiary Lupin Pharmaceuticals Inc. (LPI) entering into a settlement agreement in an ongoing antitrust litigation.
Background to the case
LPI has been part of multiple civil lawsuits in the US alleging anticompetitive practices linked to certain pharmaceutical products, alongside violations of federal and state antitrust laws. These cases were consolidated under the broader litigation titled In Re Generic Pharmaceuticals Antitrust Litigation, currently being heard in Philadelphia, Pennsylvania.
Strategic settlement decision
While maintaining that the allegations lack merit, Lupin opted for a settlement route following similar moves by other defendants in the case. The company cited the need to avoid prolonged litigation costs and uncertainties as a key factor behind the decision.
Agreement with Humana
Under the terms of the settlement, LPI will pay $30 million to Humana Inc. in exchange for a full and final release of all claims. The agreement covers not only LPI but also its current and former parents, affiliates, directors, employees and officers.
No admission of liability
Lupin has categorically stated that the settlement does not constitute any admission of wrongdoing or unlawful conduct. LPI continues to deny all allegations made against it in the litigation.
Financial impact contained
The company clarified that the settlement amount has already been accounted for in its prior consolidated financial results, limiting any incremental financial impact going forward